Medical Gazette. The first biosimilar drugs for cancer treatment could be available in a year and a half to two years. Several pharmaceutical companies are finalizing their clinical trials for rituximab and trastuzumab. Given this new scenario, scientific societies have insisted that the original drug should not be exchanged with the biosimilar in patients who have already started their treatment and who are under control.